01.11.2024  19:09:54 Zm. -0,40 Wolumen Bid21:58:00 Ask21:58:00 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
30,85EUR -1,28% 3 475
Obrót: 107 817,60
30,80Wolumen Bid: 110 31,25Wolumen Ask: 128 1,67 mldEUR 2,83% 26,77

Opis działalności

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Zarząd & Rada nadzorcza

CEO
Dr. Hans-Georg Feldmeier
Zarząd
Dr. Andreas Eberhorn, Christof Dreibholz
Rada nadzorcza
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Dane firmy

Nazwa: Dermapharm Holding SE
Adres: Lil-Dagover-Ring 7,D-82031 Grünwald
Telefon: +49-89-64186-0
Fax: +49-89-64186-130
E-mail: -
Internet: ir.dermapharm.de/index.php
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: -
Data IPO: 09.02.2018

Relacje inwestorskie

Nazwa: Britta Hamberger
Telefon: +49-89-64186-233
Fax: +49-89-64186-165
E-mail: ir@dermapharm.com

Kalendarz korporacyjny

Tydz. 46 | 14.11.2024 Raport okresowy/3. kwartał
 

Główni akcjonariusze

Themis Beteiligungs-AG
 
68,50%
FreeFloat
 
31,50%